Cobolimab  (Synonyms: 考伯利单抗; TSR-022; GSK4069889)

Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC₅₀ value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Humanized

Cobolimab (0.0001-10 nM；3 d) 在预激活 T 细胞中以剂量依赖性方式促进 TIM-3 内化，IC₅₀ 值为 0.4464 nM^[3]。
Cobolimab (20 µg/mL；24 h) 通过抑制 TIM-3 显著增加了 CD8⁺ T 细胞含量^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2022215-65-0

液体

Colorless to light yellow

考伯利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Loaded Cobolimab on AHC2 biosensor, can bind TIM-3/HAVCR2 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78217) with an affinity constant of 7.523E-10 M as determined in BLI assay.

• [1]. Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022.

  [2]. Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219.  [Content Brief]

  [3]. Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236.  [Content Brief]

  [4]. Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447.  [Content Brief]